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Intermediate monocytes in ANCA 
vasculitis: increased surface 
expression of ANCA autoantigens 
and IL-1β secretion in response to 
anti-MPO antibodies
Eóin C. O’Brien1, Wayel H. Abdulahad2, Abraham Rutgers2, Minke G. Huitema2, 
Vincent P. O’Reilly1, Alice M. Coughlan1, Mark Harrington1, Peter Heeringa3, Mark A. Little1 
& Fionnuala B. Hickey1
ANCA vasculitis encompasses several autoimmune conditions characterised by destruction of 
small vessels, inflammation of the respiratory tract and glomerulonephritis. Most patients harbour 
autoantibodies to myeloperoxidase (MPO) or proteinase 3 (PR3). Clinical and experimental data 
suggest that pathogenesis is driven by ANCA-mediated activation of neutrophils and monocytes. We 
investigated a potential role for distinct monocyte subsets. We found that the relative proportion 
of intermediate monocytes is increased in patients versus control individuals, and both MPO and 
PR3 are preferentially expressed on these cells. We demonstrate that MPO and PR3 are expressed 
independently of each other on monocytes and that PR3 is not associated with CD177. MPO 
expression correlates with that of Fc receptor CD16 on intermediate monocytes. Monocyte subsets 
respond differently to antibodies directed against MPO and PR3, with anti-MPO but not anti-PR3 
leading to increased IL-1β, IL-6 and IL-8 production. In concordance with the observed higher surface 
expression of MPO on intermediate monocytes, this subset produces the highest quantity of IL-1β in 
response to anti-MPO stimulation. These data suggest that monocytes, specifically, the intermediate 
subset, may play a role in ANCA vasculitis, and also indicate that substantial differences exist 
between the effect of anti-MPO and anti-PR3 antibodies on these cells.
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) refers to a group of severe 
multi system autoimmune diseases affecting the microvasculature1. This encompasses microscopic poly-
angiitis (MPA), granulomatosis with polyangiitis (GPA, formally known as Wegner’s granulomatosis) and 
eosinophilic granulomatosis with polyangiitis (EGPA, formerly known as Churg-Strauss syndrome). In 
most cases AAV is characterised by autoantibodies to myeloperoxidase (MPO) or proteinase-3 (PR3)2,3. 
These proteins are primarily found in the cytoplasmic granules of neutrophils and lysosomes of mono-
cytes. Substantial clinical and experimental evidence indicates that these autoantibodies drive pathogen-
esis of the disease4,5. GPA, EGPA and MPA share the same pathology of necrotising vasculitis of small 
vessels, the primary difference between them being the development of granuloma in EGPA and GPA 
but not MPA, with marked eosinophilia and asthma in EGPA. The majority of AAV research to date has 
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focused on the neutrophil as the dominant cell driving pathology, with the role of the monocyte being 
less well examined. However, similar to neutrophils, monocytes also express the antigenic targets MPO 
and PR3 and macrophages are frequently found in the vascular infiltrates of both kidneys and lungs of 
patients with AAV6. In addition, ANCA have been shown to induce the production of oxygen radicals7 
and interleukin (IL)-88 in monocytes.
For many years monocytes were classified into 2 subsets based on their expression of the Fc gamma 
III receptor, CD16 (CD16- and CD16+ monocytes). Recently, the CD16+ subset has been subdivided 
based on their surface expression of the lipopolysaccharide (LPS) co-receptor, CD14, resulting in 3 dis-
tinct monocyte populations (Table 19): classical (CD14highCD16neg/low), intermediate (CD14highCD16high) 
and non-classical (CD14lowCD16high). Classical monocytes comprise the largest subset and appear to have 
a role in proinflammatory responses as well as having antimicrobial effects. The previous roles described 
for CD16+ monocytes have yet to be fully attributed to either the intermediate or non-classical subtype, 
but intermediate monocytes appear to have a proinflammatory role while the non-classical subset have 
a patrolling and anti-viral function. ANCA stimulation of neutrophils has been shown to require the Fc 
portion of the autoantibody for full effect10, suggesting that ANCA may interact with CD16 on mono-
cytes and therefore, distinct monocyte subsets may play a key role in the pathogenesis of the disease. 
Differences in the proportion of monocyte subsets, particularly an increase in intermediate cells, has 
previously been shown in a number of autoimmune diseases including rheumatoid arthritis11, sarcoido-
sis12, and severe asthma13. We therefore postulated that distinct monocyte subsets may exhibit different 
responses to the autoantibodies associated with ANCA vasculitis.
Results
The proportion of intermediate monocytes is increased in AAV patients. Monocyte subsets 
were analysed in AAV patients (n = 100, 19 active and 81 remission), disease control patients (n = 18) 
and healthy control individuals (n = 44) (Table 2). Individual subsets were identified based on cell surface 
expression of CD14 and CD16 as measured by flow cytometry. We observed no significant difference in the 
proportion of classical and non-classical monocytes, as a percentage of total monocytes, between healthy 
controls, disease controls and AAV patients (remission or active) (Fig. 1A,C). Intermediate monocytes were 
significantly increased in both remission and active AAV patients when compared to healthy control indi-
viduals (Fig. 1B). The fraction of intermediate monocytes in the disease control group was numerically sim-













Age: Median (Range) 59 (50–70) 55 (51–73) 59 (49–70) 54 (17–87) 39 (22–75)
Gender 51 male 49 female
14 male 5 
female
37 male 44 
female
13 male 5 
female
19 male 25 
female










Proportion of patients 
on immunosuppression 72% 76% 72% 65% 0%
Median CRP (mg/dL, 
interquartile range) 3 (1–12) 15(10–64) 2 (1–7) 9 (1–34) N/A
eGFR (ml/min, 
interquartile range) 63 (42–80) 49 (35–87) 64 (42–80) 64 (18–87) N/A
Proportion 
eGFR < 60 ml/min 40% 47% 38% 44% N/A
Table 2.  Demographic and clinical information for patients and controls. All clinical data were obtained 





% in peripheral 
blood median 
(IQR)
Classical CD14highCD16neg/low Pro-inflammatory, antimicrobial 84.3 (81.4–88.8)
Intermediate CD14highCD16high Pro-inflammatory 9.4 (7.4–13.7)
Non-classical CD14lowCD16high Patrolling, Anti-viral 4.8 (2.8–7.3)
Table 1. Monocyte subset markers and phenotype (adapted from32). ‘% in peripheral blood’ refers to the 
median and interquartile range (IQR) of all samples included in this study.
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Figure 1. Intermediate monocyte subsets are increased in both active and remission AAV patients 
compared to healthy control individuals. Peripheral blood was collected from healthy control individuals, 
AAV patients (both patients with active disease and those in remission), and patients with other renal 
disease (disease controls). Percentages of monocytes in each subset (A–C) were established by flow 
cytometry based on CD14 and CD16 staining. Each symbol represents a separate individual. Data are 
presented as the median and interquartile range. (*p < 0.05, ***p < 0.005). HC: healthy control; DC: disease 
control; Rem: remission.
Figure 2. The ANCA autoantigens MPO and PR3 are preferentially expressed on intermediate 
monocytes. Peripheral blood was collected from patients with AAV and the percentage of cells expressing 
cell-surface MPO and PR3 was examined by flow cytometry. The percentage of MPO and PR3 positive cells 
in each subset is shown for (A–B) anti-MPO+ AAV patients and (C–D) anti-PR3+ AAV patients. Each 
symbol represents a separate individual. Open circles represent patients in remission and filled triangles 
patients with active disease. Data are presented as the median and interquartile range. Non-parametric one-
way ANOVA (Friedman test) and Dunn’s post-test were used to test for significance (*p < 0.05, **p < 0.01; 
****p < 0.0001). Class: classical; Int: intermediate: NC: non-classical.
www.nature.com/scientificreports/
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MPO and PR3 antigens are preferentially expressed on intermediate monocytes. We hypoth-
esised that surface expression levels of the MPO and PR3 autoantigens may vary between the different 
monocyte subsets. Using a subset of the full cohort described above and following gating on each subset, 
the percentage of monocytes expressing cell-surface MPO was significantly increased on intermediate 
cells when compared to classical and non-classical subsets (Fig. 2A,C, Supplemental Fig. S1). This find-
ing was consistent in both test and control groups, suggesting that it is a fundamental feature of the 
intermediate monocyte subset. Similarly, cell-surface PR3 expression was increased on the intermediate 
monocyte subset in both the test and control groups (Fig. 2, Supplemental Fig. S1). Following gating of 
MPO/PR3 positive cells in each subset we found a significant increase in the median fluorescence inten-
sity of MPO and PR3 on intermediate monocytes (Supplemental Fig. S2).
Monocyte surface expression of MPO and PR3 is not linked. As cell-surface expression of both 
MPO and PR3 was increased on intermediate monocytes we investigated whether expression of the two 
autoantigens was linked in this cell type. The majority of autoantigen expressing monocytes were pos-
itive for either MPO or PR3 alone, indicating that MPO and PR3 are expressed independently on the 
cell surface (Fig. 3 and Supplemental Fig. S3). These data suggest that the mechanism for anchoring the 
antigen to the plasma membrane is different in each case. In neutrophils, surface expression of CD177 
is linked to PR3 expression, with increased membrane expression of PR3 dependent on CD17714. We 
investigated whether the same mechanism accounted for surface PR3 expression on monocytes. We 
found little expression of CD177 on monocytes and no association between CD177 and PR3 (Fig. 4). As 
demonstrated previously a high proportion of PR3+ granulocytes co-expressed CD177 (Fig. 4).
CD16 expression correlates with cell-surface MPO but not PR3 expression on intermediate 
monocytes. As CD16 positivity is the criterion for differentiation between classical and intermediate 
monocytes, as well as being a potential signalling mechanism for ANCA in monocytes, we investigated 
the relationship between CD16 and MPO/PR3. Following gating on intermediate monocytes, we assessed 
whether the MPO/PR3 median fluorescence intensity was correlated with that of CD16. We found that 
surface MPO, but not PR3, was significantly correlated with CD16 (Fig. 5). Neither antigen was corre-
lated with CD16 in healthy controls, but it was correlated in disease controls (Supplemental Fig. S4), 
suggesting that this may be a feature of either renal dysfunction or systemic inflammation.
Antibodies directed against MPO stimulate IL-1β, IL-6 and IL-8 production in monocytes. To 
investigate activation of monocytes following binding of ANCA to surface antigen, we measured release 
of pro-inflammatory cytokines IL-1β , IL-6, IL-8 and IL-12p70. Monocytes were purified from peripheral 
blood mononuclear cells (PBMCs) by positive selection based on CD14 expression, primed with tumour 
necrosis factor (TNF)-α and stimulated with either monoclonal antibodies (mAb) directed against MPO 
or PR3 or with immunoglobulin G (IgG) purified from the plasma of patients with AAV. Treatment 
with anti-MPO mAb resulted in significantly increased IL-1β , IL-6 and IL-8 production (Fig. 6A). This 
increase in inflammatory cytokine production was also observed when monocytes were stimulated with 
IgG purified from anti-MPO+ AAV patients (Fig. 6B). Interestingly, this effect was not seen in monocytes 
Figure 3. Cell-surface expression of MPO and PR3 is not linked on monocytes. Peripheral blood 
was collected from patients with AAV and the percentage of cells expressing surface MPO and PR3 was 
examined by flow cytometry. Cells were classified as being MPO+ PR3-, MPO–PR3+ , MPO+ PR3+ . 
Data are presented for (A) anti–MPO+ patients and (B) anti-PR3+ patients. Each symbol represents an 
individual patient. Open circles represent patients in remission and filled triangles patients with active 
disease. Data are presented as the median and interquartile range. Non-parametric one-way ANOVA 
(Friedman test) and Dunn’s post-test were used to test for significance (**p < 0.01).
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stimulated with either mAb directed against PR3 (Fig.  6C) or protein G purified IgG from anti-PR3+ 
AAV patients (Fig. 6D). Secretion of IL-12p70 was not detected under any of the conditions tested.
Cytokine production in response to stimulation with anti-MPO mAb varies between mono-
cyte subsets. As we found MPO to be differentially expressed on different monocyte subsets, we next 
investigated if the production of IL-1β , IL-6 and IL-8 observed following stimulation of total monocytes 
differed in a subset-specific manner. Classical, intermediate and non-classical cells were sorted from 
MACS purified monocytes based on CD14 and CD16 expression (Supplemental Fig. S5). Sorted cells 
were primed with TNF-α and treated with anti-MPO mAb. This stimulation failed to induce secretion of 
any of the cytokines tested (IL-1β ; IL-6; IL-8) from non-classical monocytes (Fig. 7A–C). IL-1β produc-
tion was found to vary most between monocyte subsets, with intermediate monocytes producing higher 
quantities than classical monocytes both basally and in response to anti-MPO stimulation (Fig. 7A). IL-6 
production was found to be similar in classical and intermediate monocytes and to be increased in both 
subsets following incubation of cells with anti-MPO (Fig. 7B). Conversely only classical monocytes were 
found to secrete IL-8 in response to anti MPO mAb (Fig. 7C).
IL-1β production in response to anti-MPO is not dependent on Fc binding in monocytes. It 
has been shown previously that the binding of the Fc portion of ANCA antibodies to neutrophils is 
required for their activation10. This finding, along with our own finding that the Fc receptor (CD16) 
expression on monocytes correlates with expression of MPO led us to investigate whether blocking the Fc 
receptor would abrogate the effect of anti-MPO stimulation in monocytes. In order to test this hypothesis 
we treated cells with anti-MPO mAb after pre-treatment with either commercially available Fc blocking 
Figure 4. PR3+ monocytes do not co-express CD177. Peripheral blood was collected from healthy control 
individuals, patients with AAV and disease controls and analysed by flow cytometry. Following gating on 
monocytes or granulocytes the percentage of PR3+ cells in each population which co-express CD177 was 
determined (A). Representative histograms show the median fluorescence intensity (MFI) of CD177 on 
monocytes and granulocytes (B). Data represent the median and interquartile range. Paired t-test was used 
to test for significance (**p < 0.01). Mono: monocytes; Gran: granulocytes; FMO: fluorescence minus one 
control.
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solution or vehicle. Monocyte activation was measured by IL-1β production. Treatment with Fc blocking 
solution had no effect on the ability of anti-MPO mAb to activate monocytes (Fig. 8).
Discussion
At the time that the stimulatory effect of ANCA on neutrophils was first described, a similar phenomenon 
was described in monocytes15. ANCA were shown to stimulate oxygen radical production7 and to induce 
production of inflammatory cytokines such as IL-8 from monocytes8. Following these initial studies, the 
focus of research has been almost exclusively on neutrophils. As several autoimmune diseases, including 
rheumatoid arthritis, sarcoidosis and severe asthma11–13 are characterised by an expansion of interme-
diate monocytes, we postulated that ANCA vasculitis would also display this phenotype. We report for 
the first time that the proportion of intermediate monocytes found in AAV patients is increased when 
compared to healthy control individuals. In addition, we demonstrate that the autoantigens associated 
with ANCA vasculitis (MPO and PR3) are differentially expressed on distinct monocyte subsets, with 
the highest expression being seen on intermediate cells. In concordance with cell surface expression of 
MPO on monocytes we confirm that stimulation with anti-MPO antibodies results in monocyte acti-
vation, as measured by IL-1β , IL-6 and IL-8 production, although anti-PR3 antibodies did not have 
this effect. Importantly, we also demonstrate that monocyte subsets respond differently to anti-MPO 
antibodies, with intermediate monocytes producing the highest amount of IL-1β and increased IL-6 
following stimulation.
We first divided the AAV patients into those with active disease and those who were in remission based 
on the hypothesis that those patients with active disease would have increased inflammatory monocytes. 
We found that both remission and active patients had an increased proportion of intermediate monocytes 
Figure 5. MPO and CD16 expression are correlated on intermediate monocytes. Peripheral blood 
was collected from patients with AAV and analysed by flow cytometry. Following gating on intermediate 
monocytes the MFI of CD16 was plotted against that of MPO or PR3. Data presented show (A–B) 
anti-MPO+  AAV patients, (C–D) anti-PR3+  AAV patients. Each symbol represents an individual 
patient. Open circles represent patients in remission and filled triangles show patients with active 
disease. Correlation was tested by Spearman Rank Test.
www.nature.com/scientificreports/
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when compared to the proportions observed in healthy control individuals, This indicates that this cell 
type is expanded in patients and therefore may play a role in disease pathogenesis or pathophysiology.
We also analysed the expression of the autoantigens targeted by ANCA on monocyte subsets. It 
has been reported that monocytes express both MPO and PR3 on their cell surface16,17 although their 
expression on different monocyte subsets has not been reported. We found that both of these antigens 
are expressed preferentially on intermediate monocytes when compared to the classical and non-classical 
populations. Although intermediate cells account for a relatively small fraction of total monocytes in 
peripheral blood (6–11% in healthy individuals), the proportion of this monocyte subset is increased in 
ANCA patients. This increase, in combination with increased expression of the autoantigens, suggests 
that this subset may be the monocyte target of ANCA. Not only do an increased proportion of inter-
mediate monocytes express these antigens, but these cells express a greater amount of MPO or PR3 on 
their surface than their classical or non-classical equivalents. Taken together these data suggest that the 
intermediate subset is the monocyte population which is most susceptible to ANCA stimulation.
In anti-MPO+ AAV patients the correlation between surface MPO and CD16 on intermediate mono-
cytes indicates that expression of these two molecules may be linked. In neutrophils, ANCA have been 
shown to induce the activation of the cell through first binding to MPO or PR3 and subsequent signalling 
Figure 6. Stimulation of monocytes with anti-MPO mAb or with anti-MPO+ ANCA leads to increased 
IL-1β, IL-6 and IL-8 production. CD14+ monocytes were isolated from healthy controls PBMCs by 
MACS separation. The cells were plated and incubated with 5 ng/ml TNF-α @ 37 °C for 30 minutes and 
then stimulated for 4 hours with 5 μ g/ml of either (A) monoclonal antibody (mAb) directed against MPO, 
(B) protein G purified IgG from anti-MPO+ patients, (C) mAb against PR3 or (D) IgG purified from 
anti-PR3+ patients. Supernatants were then removed and levels of IL-1β , IL-6 and IL-8 measured by ELISA. 
Data are presented as the median and interquartile range of the fold increase over control. Statistical analysis 
was performed using Wilcoxon signed rank test (*p < 0.05, **p < 0.01, ****p < 0.0001). Iso: isotype control; 
CTRL: Control.
www.nature.com/scientificreports/
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through their Fc region10. As CD16 is an Fc receptor its expression on the same cells as MPO may pro-
vide an insight into the possible activation of these cells by anti-MPO ANCA. The differential nature of 
surface MPO and PR3 expression is highlighted by the fact that in AAV patients CD16 is only correlated 
with MPO but not PR3. The significance of this finding remains to be determined as we have found 
that Fc receptor binding is not required for the induction of IL-1β by anti-MPO. It has been shown that 
Figure 7. Intermediate monocytes produce increased amounts of IL-1β and IL-6 both basally and in 
response to stimulation with anti-MPO mAb. CD14+ monocytes were isolated from PBMCs of healthy 
control individuals by MACS separation. Monocyte subsets were then sorted from CD14+ cells based 
on CD14 and CD16 expression. Sorted subsets of cells were incubated with 5 ng/ml TNF-α @ 37 °C for 
30 minutes followed by stimulation for 4 hours with 5 μ g/ml of either monoclonal antibody (mAb) directed 
against MPO or an isotype control. Supernatants were then removed and levels of (A) IL-1β , (B) IL-6 and 
(C) IL-8 measured by ELISA. Data are presented as the median and interquartile range of the fold increase 
over control. Statistical analysis was performed using Two-way ANOVA and Sidak test to correct for 
multiple comparisons (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Class: Classical; Int: Intermediate; 
NC: Non-Classical
www.nature.com/scientificreports/
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CD16 expression occurs in lipid rafts18. While CD16 is not directly required for signalling in response to 
anti-MPO stimulation, the correlation between MPO and CD16 may indicate that lipid raft formation is 
occurring and therefore other glycosylphosphatidylinositol (GPI)-linked proteins may be involved in the 
response to anti-MPO antibodies. Another way in which monocytes appear to differ from neutrophils is 
the way in which they express PR3 on their surface. In neutrophils, surface translocation of PR3 usually 
occurs through an association with CD17714. This does not appear to be the mechanism in monocytes; 
elucidation of how both PR3 and MPO traffic and remain on the plasma membrane of monocytes, as 
well as presumably facilitating an outward-in signalling process, will need to be examined closely. CD177 
is thought to form a signalling complex through which neutrophils are stimulated following binding of 
antibodies to PR319. As we have shown, monocytes lack CD177 on their surface and this may explain 
why stimulation with PR3 antibodies does not lead to IL-1β production in these cells.
It has been shown previously that mAbs directed against both MPO and PR3 lead to the production of 
IL-1β from monocytes20. However, our data demonstrate that only anti-MPO and not anti-PR3 stimula-
tion leads to the activation and subsequent IL-1β production from monocytes. The discrepancy between 
these two results may be due to the fact that monocytes were isolated by different methods. We have used 
a positive magnetic bead selection method, whereas Schreiber et. al. used a plastic adherence method in 
order to purify their monocytes. It has been shown previously that adherence of monocytes to plastic can 
result in partial activation of the cells21. This activation may account for the differences in IL-1β produc-
tion in response to ANCA stimulation.. We have shown a similar result when mAbs were replaced with 
IgG derived from anti-MPO + and anti-PR3+ patients, with only IgG from anti-MPO+ patients leading 
to IL-1β production, further verifying the specificity of the response. This specific anti-MPO response 
is also observed when we investigated other inflammatory cytokines, IL-6 and IL-8. The production of 
these cytokines mirrored the pattern observed in IL-1β production from the stimulated total monocyte 
population.
In order to investigate our hypothesis that the intermediate subset of monocytes, by virtue of their 
increased antigen expression, would have the greatest response to anti-MPO antibodies we used a similar 
system of stimulation to that used for total monocytes. For these experiments we went a step further 
and sorted the individual monocyte subsets based on their CD14 and CD16 expression. This allowed us 
to analyse the individual subsets and therefore show how each group was contributing to the response 
to antibody stimulation which we had seen previously. Stimulation of the intermediate subset led to 
the highest production of IL-1β . The magnitude of the increase in anti-MPO induced IL-1β in sorted 
monocytes was not as high for any of the subsets as had been observed in total monocytes. This is 
likely a consequence of the additional MoFlo sorting procedure, which may have partially activated the 
cells prior to stimulation. This monocyte subset has previously been shown to produce a number of 
cytokines in response to LPS22; however, their response to ANCA has not been studied until now. We 
have shown that the three monocyte subsets each have a different cytokine profile following stimulation 
with anti-MPO antibodies. While the intermediate monocytes showed the greatest increase in IL-1β pro-
duction, the amount of IL-6 produced in these cells was comparable to that seen in the classical subset. 
Conversely, the IL-8 production observed in response to ANCA stimulation of monocytes was shown 
to be exclusively a product of the classical subset. Interestingly, secretion of each of these cytokines was 
unchanged in the non-classical subset in response to ANCA stimulation. Previous studies have attempted 
Figure 8. Fc receptor binding is not required for anti-MPO-induced IL-1β production by monocytes. 
CD14+ monocytes were isolated from PBMCs of healthy control individuals by MACS separation. Cells 
were incubated with 2.5 μ g/1 × 106 cells Fc Block @ 37 °C for 30 minutes followed by stimulation for 
4 hours with 5 μ g/ml of either monoclonal antibody (mAb) directed against MPO or an isotype control. 
Supernatants were then removed and levels of IL-1β measured by ELISA. Data are presented as the median 
and interquartile range. Statistical analysis was performed using Two-way ANOVA and Sidak test to correct 
for multiple comparisons (**p < 0.01).
www.nature.com/scientificreports/
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to classify the three monocyte subsets based on their differential cytokine production, which also serve 
to underline the complex nature of cytokine release by each subset22,23.
It is unclear whether intermediate monocytes represent a transitional cell type or whether they are 
a functionally distinct cell population. Our data clearly support a distinct functional role for these cells 
as they differ from both classical and non-classical monocytes in terms of autoantigen expression, pro-
duction of the pro-inflammatory cytokine IL-1β , and response to ANCA. For all of these parameters, 
non-classical cells were more similar to the classical subset than they were to the intermediate, suggesting 
that intermediate monocytes are not a transitional population.
The production of IL-1β has been shown to play a critical role in the pathogenesis of ANCA vasculitis, 
with the IL-1 receptor antagonist anakinra protecting against glomerulonephritis in an anti-MPO-induced 
mouse model20. By sorting of individual monocyte subsets we show that intermediate monocytes pref-
erentially express the autoantigens associated with AAV and that these cells produce the highest levels 
of IL-1β in response to anti-MPO, suggesting a possible key role for these cells in AAV. It is likely that 
activated monocytes, in combination with neutrophils, are responsible for initial pathologic responses to 
ANCA in patients. In this context, IL-1β has been shown to prime neutrophils for activation24, suggesting 
that activated monocytes may contribute to neutrophil activation. Our data demonstrating the induc-
tion of IL-1β , IL-6 and IL-8 by anti-MPO but not anti-PR3 antibodies highlights differences between 
the two primary autoantigens associated with AAV. It is increasingly appreciated that MPO-ANCA 
and PR3-ANCA vasculitis are different diseases both genetically and phenotypically25. The presence of 
anti-PR3 antibodies portends a high relapse rate26 and granulomatous disease affecting the upper and 
lower respiratory tract27,28, while the presence of anti-MPO antibodies is associated with a more “vascu-
litic” phenotype with a high incidence of scarring in kidney and lung at the time of diagnosis2,28. While 
mechanistic explanations linking the current work with these observations are beyond the scope of this 
manuscript, monocytes and macrophages are important in both the generation of granuloma29 and pro-
gression of fibrosis, so it is conceivable that the differential effect of anti-PR3 and anti-MPO antibodies 
on these cells is important in cellular pathogenesis. For example, the MCP1 / CCR2 chemokine axis is 
known to be pro-fibrotic30 and may be preferentially activated by anti-MPO antibodies. Further investi-
gation to understand this differential effect and its link to clinical phenotype is ongoing.
Methods
Patients and control individuals. Blood samples from patients and both healthy and disease control 
individuals were obtained through the Rare Kidney Disease (RKD) Biobank and University Medical 
Center Groningen and written consent was obtained from all individuals. The RKD Biobank has full 
approval from the Trinity College Dublin Institutional Review Board and Ethics Committee, and 
approval from each of the individual hospitals from which samples were obtained (St. James’ hospi-
tal, Tallaght hospital and Beaumont hospital). Similarly, collection of samples at the University Medical 
Center Groningen was conducted according to local ethical guidelines and approved by the ethical com-
mittee of the University Medical Center Groningen, and in accordance with the Declaration of Helsinki. 
All AAV patients fulfilled the Chapel Hill Consensus Conference (CHCC) classification criteria31. Active 
vasculitis was defined as a Birmingham vasculitis activity score (BVAS) > 3. Where possible, blood was 
collected from active patients prior to commencement of immunosuppression therapy. Four (24%) and 
twenty three (28%) of the active and remission patients with AAV were on no immunosuppression at 
the time of sampling. Antibodies against MPO and PR3 were determined by ELISA. The disease con-
trol group comprised patients with anti-glomerular basement membrane (anti-GBM) disease (n = 2), 
Takayasu’s arteritis (n = 1), uveitis (n = 1), isolated leukocytoclastic vasculitis (n = 1), IgA nephropathy 
(n = 1), lupus nephritis (n = 1), non-immune chronic kidney disease (n = 4), triple vessel coronary artery 
disease (n = 1), pyelonephritis (n = 1), cirrhosis (n = 1), megaloblastic anemia (n= 1), end stage kidney 
disease due to ischemic nephropathy (n = 1), vascular dementia (n= 1) and minimal change glomeru-
lonephritis (n = 1).
Flow cytometry. Peripheral blood was collected in ethylene diamine tetra-acetic acid (EDTA). 
Staining was performed in 100 μ l of whole blood. The volume of each antibody used was 5 μ l per 100 μ l of 
blood. Samples were stained for 20 minutes in the dark with anti-CD14 Pacific Blue (RMO52, Beckman 
Coulter), anti-CD16 APC (3G8, Biolegend), anti-CD66b PerCP-Cy5.5 (G10F5, BD Biosciences), anti-PR3 
FITC (W6M2, Abcam) and either anti-MPO PE (2C7, Serotec) or anti-CD177 PE (MEM-166, Molecular 
Probes). Red blood cells were lysed using 2 ml of BD FACS lysing solution diluted 1 in 10 in dH2O. The 
remaining cells were fixed with 500 μ l of 2% paraformaldehyde. Flow cytometry was performed on a 
CyAn ADP analyser (Beckman Coulter). Single stain OneComp beads (eBioscience) and fluorescence 
minus one (FMO) controls were used to correct for spectral overlap and non-specific staining respec-
tively. FACS analysis was performed using Kaluza v1.2 flow analysis software (Beckman Coulter).
Monocyte subset analysis. Monocytes were gated first on size and granularity. Doublet cells were 
excluded by plotting FSC against FSC-area. Gating on CD66b positive cells (granulocytes) was used 
to exclude these cells from subsequent analyses. Monocytes were identified as CD66b negative, CD14 
positive cells. Following gating on monocytes identified in this manner the percentage of each sub-
set was calculated based on CD16 and CD14 expression (classical: CD14highCD16neg/low; intermediate: 
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CD14highCD16high: non-classical: CD14lowCD16high) (Supplemental Fig. S6). The percentage of MPO and 
PR3 positive cells was determined using gates set with FMO controls (Supplemental Fig. S7).
Purification of monocytes and sorting of monocyte subsets. Peripheral blood was collected 
in EDTA. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifuga-
tion using lymphoprep (Axis-Shield) and monocytes were purified by positive selection. PBMCs were 
incubated with anti-CD14 magnetic beads (Miltenyi Biotec) as per the manufacturer’s instructions and 
CD14+ cells were then isolated using an LS column on a QuadroMACS separator (Miltenyi Biotec). In 
experiments where monocytes were further sorted into distinct subsets, cells were stained by incubat-
ing with 5 μ l of CD14 PE-Cy7 (M5E2, Biolegend) and CD16 APC (3G8, Biolegend) per 1 × 105cells for 
20 minutes. Cells were washed and monocyte subsets were sorted based on their expression of CD14 and 
CD16 using a MoFlo XDP analyser (Beckman Coulter) (Supplemental Fig. S5).
Stimulation of monocytes and measurement of IL-1β, IL-6 and IL-8 secretion. Total CD14+ 
monocytes or individual monocyte subsets were isolated as detailed above. Cells were then plated in 
Roswell Parks Memorial Media (RPMI) supplemented with 10% fetal calf serum (FCS), 100 U/ml peni-
cillin, 1 mg/ml streptomycin and 2 mM l-glutamine. Cells were seeded at a density of 5 × 105 cells/well 
for total monocytes, or 3 × 105 cells/well for sorted subsets. The cells were incubated with 5 ng/ml TNF-α 
@ 37 °C for 30 minutes as used previously20 and then stimulated with 5 μ g/ml of either monoclonal anti-
body (mAb) directed against MPO (2C7, Acris Antibodies) or PR3 (CLB-12.8, HiSS Diagnostics GmbH) 
or isotype control antibody (IgG1, Acris Antibodies), protein G purified IgG from anti-MPO + (n = 3) or 
anti-PR3 + (n = 3) patients or healthy controls (n = 4) for 4 hours. Supernatants were removed and IL-1β , 
IL-6 or IL-8 ELISA was performed as per the manufacturer’s instructions (R&D Systems).
Fc blocking of stimulated monocytes. Monocytes were isolated and plated as detailed above. The 
cells were incubated with 2.5 μ g Fc block (BD Biosciences)/1 × 106 cells @ 37 °C for 30 minutes and 
then stimulated with 5 μ g/ml of either monoclonal antibody (mAb) directed against MPO (2C7, Acris 
Antibodies) or isotype control antibody (IgG1, Acris Antibodies) for 4 hours. Supernatants were removed 
and IL-1β ELISA was performed as per the manufacturer’s instructions (R&D Systems).
Statistical analysis. All statistics and correlations were performed using GraphPad Prism 6 soft-
ware and nonparametric analyses were used for non-normal data. When comparing 3 or more groups, 
a Kruskal-Wallis test was performed for unpaired samples and a post hoc Friedman test was used for 
paired samples. Multiple comparisons were corrected using Dunn’s multiple comparisons test. For com-
parisons between 2 groups, a two-tailed Mann Whitney test was used. Correlation was assessed using the 
Spearman rank test. To assess the difference in cytokine production between anti-MPO and isotype mAb 
across the 3 subsets 2-way ANOVA with Sidak’s post hoc multiple comparison test was used. Differences 
were not statistically significant (p < 0.05) unless specified.
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